Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of a Chlamydia Trachomatis mRNA Vaccine Candidate in Adults
NCT06891417Phase 1Recruiting
- Sponsor
- Sanofi
- Start
- Mar 2025
- Primary completion
- Nov 2027
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised trial of chlamydia trachomatis mrna vaccine in Chlamydia trachomatis infection (6 cohorts), sponsored by Sanofi. Primary endpoints: Presence of immediate unsolicited systemic adverse events at 30 minutes, Presence of solicited injection site and systemic reactions at 8 days and 5 more. Started Mar 2025; status: recruiting.
02
Drugs
chlamydia trachomatis mrna vaccine
03
Conditions
Chlamydia trachomatis infection
Beyond the preview
Go deeper on NCT06891417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06891417.